We are live on ! Find out more
BBH icon

VanEck Biotech ETF

110 hedge funds and large institutions have $152M invested in VanEck Biotech ETF in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 31 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less funds holding

Funds holding: 111 → 110 (-1)

4.05% less ownership

Funds ownership: 37.62% → 33.56% (-4.1%)

39% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 31

72% less capital inflows, than outflows

Capital inflows: $10.1M | Capital outflows: $35.5M

Holders
110
Holders Change
-1
Holders Change %
-0.9%
% of All Funds
1.74%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
19
Reduced
31
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BBH Hedge Fund Activity: Q3 2023 in Review

110 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2023, worth a combined $152M — down 16% from $180M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new BBH positions and 9 closed out — a net gain of 2 holders — while 19 added to existing stakes and 31 trimmed.

The largest buyer was Valley Wealth Managers, opening a new position worth an estimated $3.03M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $9.9M.

  • 110 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2023, down from 111 in Q2 2023.
  • Funds reported $152M of VanEck Biotech ETF stock for Q3 2023, down 16% quarter-over-quarter.
  • 11 funds opened new VanEck Biotech ETF positions in Q3 2023 and 9 closed out, a net change of +2 holders.
  • The largest VanEck Biotech ETF buyer in Q3 2023 was Valley Wealth Managers, an estimated $3.03M added.
  • The largest VanEck Biotech ETF seller in Q3 2023 was Qube Research & Technologies (QRT), an estimated $9.9M sold.

Based on aggregated 13F filings for Q3 2023.